Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Drug Discovery > 2026 Vol. 1 > No. 3 > 100044
Next Article Previous Article
COMMENTARY   Open Access     Cite

B cells as promising drug targets for autoimmune diseases

  • 1.

    Division of Immunology and Rheumatology, Department of Medicine, Stanford University, 269 Campus Drive, Stanford CA 94305, USA

  • 2.

    VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto CA 94304, USA

  • 3.

    Institute of Systems Medicine and Health Sciences, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China

  • 4.

    Department of Nephrology, Leiden University Medical Center, Leiden 2300 RC, Netherlands

More Information
  • Corresponding authors: wuxh@stanford.edu (X.W.)
  • Received Date:  July 31, 2026
    Accepted Date:  September 28, 2026
    Published Online:  October 09, 2026
The Innovation Drug Discovery  1(3),  https://doi.org/10.59717/j.xinn-drugdisc.2026.100044  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Müller F., Hagen M., Wirsching A., et al. (2026). CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nat. Med. 32:1142−1151. DOI:10.1038/s41591-025-04185-6

    View in Article CrossRef Google Scholar

    [2] Wang X., Wu X., Tan B., et al. (2024). Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187:4890−4904.e4899. DOI:10.1016/j.cell.2024.06.027

    View in Article CrossRef Google Scholar

    [3] Düsing C., Györfi A.-H., Stütz A. N., et al. (2026). Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat. Med. 32:1530−1542. DOI:10.1038/s41591-026-04238-4

    View in Article CrossRef Google Scholar

    [4] He Z., Glass M. C., Venkatesan P., et al. (2025). Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation. Sci. Transl. Med. 17:eadt7214. DOI. DOI:10.1126/scitranslmed.adt7214

    View in Article CrossRef Google Scholar

    [5] Wu X., Zhang M., Moon J.-S., et al. (2026). Senescent-like Activated Naive B Cells Contribute to the Progression to Clinical Rheumatoid Arthritis. Nat. Aging. In press.

    View in Article Google Scholar

    • Cited by

  • Cite this article:

    Wu X. and van Dam L.S. (2026). B cells as promising drug targets for autoimmune diseases. The Innovation Drug Discovery 1:100044. https://doi.org/10.59717/j.xinn-drugdisc.2026.100044
    Wu X. and van Dam L.S. (2026). B cells as promising drug targets for autoimmune diseases. The Innovation Drug Discovery 1:100044. https://doi.org/10.59717/j.xinn-drugdisc.2026.100044

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(131) PDF downloads(75)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Published articles are licensed under CC BY with copyright retained by the authors.
    All contents on this site: Copyright © 2026 INNOVATION PRESS. All rights are reserved.